Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Cash from Investing Activities: 2015-2025

Historic Cash from Investing Activities for AC Immune (ACIU) over the last 10 years, with Sep 2025 value amounting to $59.4 million.

  • AC Immune's Cash from Investing Activities rose 2567.06% to $59.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.3 million, marking a year-over-year increase of 200.32%. This contributed to the annual value of -$120.2 million for FY2024, which is 262.41% down from last year.
  • According to the latest figures from Q3 2025, AC Immune's Cash from Investing Activities is $59.4 million, which was up 106.00% from $28.8 million recorded in Q2 2025.
  • AC Immune's 5-year Cash from Investing Activities high stood at $59.4 million for Q3 2025, and its period low was -$83.8 million during Q2 2024.
  • Moreover, its 3-year median value for Cash from Investing Activities was $3.4 million (2025), whereas its average is $4.2 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first spiked by 8,013.88% in 2023, then plummeted by 1,362.29% in 2024.
  • Over the past 5 years, AC Immune's Cash from Investing Activities (Quarterly) stood at -$23.6 million in 2021, then skyrocketed by 121.85% to $5.1 million in 2022, then skyrocketed by 409.85% to $26.2 million in 2023, then tumbled by 116.64% to -$4.4 million in 2024, then surged by 2,567.06% to $59.4 million in 2025.
  • Its Cash from Investing Activities stands at $59.4 million for Q3 2025, versus $28.8 million for Q2 2025 and $3.4 million for Q1 2025.